News
Pfizer Announces Additional Phase 2/3 Study Results Confirming Robust Efficacy of Novel COVID-19 Oral Antiviral Treatment Candidate in Reducing Risk of Hospitalization or Death
Pfizer Inc. (NYSE: PFE) today announced final results from an analysis of all 2,246 adults enrolled in its Phase 2/3 EPIC-HR (Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients)
Poxel Announces its Participation at Upcoming Investor and Scientific Conferences in January 2022
POXEL SA (Euronext – POXEL – FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including
CSL Limited announces tender offer to acquire Vifor Pharma Ltd
Regulatory News:
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Global biotechnology leader CSL Limited (ASX: CSL; USOTC:CSLLY) and Vifor Pharma Ltd (SIX:VIFN; ISIN:CH0364749348), a global
DGAP-News: Biotest AG: Biotest treats first CMV-positive pregnant woman in Phase III clinical trial to prevent transmission of CMV infection to the unborn child
DGAP-News: Biotest AG: Biotest behandelt erste CMV-positive Schwangere in klinischer Phase III-Studie zur Prävention einer Übertragung der CMV-Infektion auf das ungeborene Kind
GeNeuro erhält von der Schweizer Regierung Finanzmittel in Höhe von 6,7 Millionen Schweizer Franken (6,4 Millionen Euro) für die Entwicklung von Temelimab gegen Long COVID
GeNeuro (Euronext Paris: CH0308403085 - GNRO) (Paris:GNRO), ein biopharmazeutisches Unternehmen, das neue Therapien für neurodegenerative und Autoimmunerkrankungen entwickelt, meldete heute, dass
Navidea Biopharmaceuticals Announces Third-Party Asset Valuation of Tc99m Tilmanocept for Indications in Rheumatoid Arthritis
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today
Pfizer to Acquire Arena Pharmaceuticals
Pfizer Inc. (NYSE: PFE) and Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the companies have entered into a definitive agreement under which Pfizer will acquire Arena, a clinical
Vifor Pharma comments on media speculation
Regulatory News:
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Vifor is in discussions with CSL about a possible transaction. No decisions have been made yet and there is no time frame for this
Geneuro Receives CHF 6.7 Million (EUR 6.4 Million) in Funding From the Swiss Government for the Development of Temelimab Against Long-COVID
Regulatory News:
GeNeuro (Euronext Paris: CH0308403085 - GNRO) (Paris:GNRO), a biopharmaceutical company developing novel treatments for neurodegenerative and autoimmune diseases, with final
Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Bleeding Control in Highest Dose Cohort Through Two Years Following Hemophilia A Gene Therapy
Pfizer Inc. (NYSE: PFE) and Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced updated follow-up data from the Phase 1/2 Alta study of giroctocogene
Sangamo Therapeutics Announces Updated Preliminary SAR445136 Phase 1/2 Proof-of-Concept Data Showing Tolerability and Sustained Effects in Sickle Cell Disease
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced updated preliminary proof-of-concept clinical data from the Phase 1/2 PRECIZN-1 study of SAR445136, a zinc
DGAP-News: MorphoSys präsentiert neueste Daten der MANIFEST Phase 2-Studie zur Bewertung des Potenzials von Pelabresib bei der Behandlung von Myelofibrose
DGAP-News: MorphoSys presents latest data from the Phase 2 MANIFEST Study evaluating the potential of pelabresib in the treatment of myelofibrosis
Xencor Presents Data from Phase 1 Study of Plamotamab in B-cell Non-Hodgkin Lymphomas at the ASH Annual Meeting
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced
DGAP-News: MorphoSys und Incyte geben weitere 'Real World' Ergebnisse der RE-MIND2-Studie mit Tafasitamab (Monjuvi(R)) in Kombination mit Lenalidomid zur Behandlung des R/R DLBCL bekannt
DGAP-News: MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi(R)) in Combination with Lenalidomide for the Treatment of r/r DLBCL
Puma Biotechnology Presents Updates from the SUMMIT Trial at the 2021 SABCS Annual Meeting
Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, presented an update from its Phase II SUMMIT trial at the ongoing 2021 San Antonio Breast Cancer Symposium (SABCS) Annual
First patient enrolled in phase-IIa study of vamifeport in patients with sickle cell disease
Vifor Pharma today announced that the first patient has been enrolled in a double-blind, randomized phase-IIa clinical trial evaluating the safety, efficacy and tolerability of vamifeport in adult
Pfizer Declares First-Quarter 2022 Dividend
Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared an increase in the quarterly cash dividend on the company’s common stock to $0.40 for the first-quarter 2022 dividend
European Commission Approves Pfizer’s Cibinqo® (abrocitinib) for the Treatment of Adults with Moderate-to-Severe Atopic Dermatitis
Pfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) has approved the 100 mg and 200 mg doses of Cibinqo® (abrocitinib), an oral, once-daily, Janus kinase 1 (JAK1) inhibitor
Vifor Pharma appoints Hervé Gisserot as new Chief Commercial Officer and member of the Executive Committee
Regulatory News:
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Vifor Pharma Group today announced the appointment of Hervé Gisserot as Chief Commercial Officer and member of the Vifor Pharma
Vifor Pharma and Angion report topline results from phase-II GUARD trial of ANG-3777 in cardiac surgery associated acute kidney injury
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211209006035/en/
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Vifor
DGAP-News: Record revenue for Carl Zeiss Meditec in fiscal year 2020/21
DGAP-News: Carl Zeiss Meditec erzielt Rekordumsatz im Geschäftsjahr 2020/21